What Happened?
A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.
The Health Care Select Sector SPDR Fund slipped 0.91% in regular trading, according to exchange data. CMS canceled approximately 315,000 enrollments covering over 760,000 individuals following an investigation into unauthorized sign-ups, the agency said in a fact sheet. The administration expects the purge to recoup roughly $2.2 billion in advance premium tax credits, according to CNBC. Rulemaking records show the agency also paused new broker registrations through February 2027 and will review 419,000 additional enrollees.
Because federal premium tax credits flow directly to health plans rather than enrollees, policy terminations immediately cut exchange revenue. Healthcare companies like Centene and Molina write significant marketplace volume, leaving their toplines more exposed to membership purges than commercial peers. Halting broker onboarding also risks crimping sign-ups ahead of open enrollment on November 1. The crackdown shifts the exchange thesis from enrollment growth to regulatory friction. With broker channels restricted and verification tightening, exchange-focused insurers face a shrinking addressable market and higher acquisition costs into the next plan year.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Specialty Pharmaceuticals company Ocular Therapeutix (NASDAQ: OCUL) fell 6.7%. Is now the time to buy Ocular Therapeutix? Access our full analysis report here, it’s free.
- Generic Pharmaceuticals company ANI Pharmaceuticals (NASDAQ: ANIP) fell 4.3%. Is now the time to buy ANI Pharmaceuticals? Access our full analysis report here, it’s free.
Zooming In On Ocular Therapeutix (OCUL)
Ocular Therapeutix’s shares are extremely volatile and have had 47 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 6 months ago when the stock gained 12.4% on the news that the company announced it had completed the first patient enrollment in the Phase III clinical trial for its dry eye disease treatment, OT-211, in China.
The treatment, OT-211 (AR-15512), is a 0.003% concentration eye drop formulation. It is also the first TRPM8 agonist approved by the U.S. Food and Drug Administration for this condition. According to the announcement, the successful enrollment of the first patient marked a significant milestone in the clinical development of OT-211 in China. The company stated this event reflected its commitment to advancing innovative therapies for patients suffering from dry eye disease.
Ocular Therapeutix is down 13.8% since the beginning of the year, and at $10.19 per share, it is trading 36.7% below its 52-week high of $16.11 from December 2025. Investors who bought $1,000 worth of Ocular Therapeutix’s shares 5 years ago would now be looking at only $939.54.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
